The company depends on third-party manufacturers for raw materials used in producing product candidates for clinical trials and potential commercial sale, without direct control over acquisition processes or timing. Delays or disruptions in supply, including the need to replace manufacturers, could significantly impact clinical trial timelines and regulatory approvals. The SLS-002 product, a drug-device combination consisting of ketamine hydrochloride and a USP aqueous spray solution delivered via a bi-dose nasal device developed by a third party under a license agreement, faces additional regulatory challenges. Manufacturing facilities and contract manufacturers are required to comply with regulations such as current Good Manufacturing Practices (cGMP) and Good Laboratory Practices (GLP) to ensure quality and regulatory compliance. Inadequate manufacturing controls could introduce contaminants or affect product stability, thereby impacting safety and effectiveness. Documentation supporting New Drug Application (NDA) or Marketing Authorization Application (MAA) submissions must be prepared in a timely manner and comply with regulations set by the FDA, EMA, or comparable foreign authorities.
Seelos Therapeutics Inc's Comment on Supply Chain
The company depends on third-party manufacturers for raw materials used in producing product candidates for clinical trials and potential commercial sale, without direct control over acquisition processes or timing. Delays or disruptions in supply, including the need to replace manufacturers, could significantly impact clinical trial timelines and regulatory approvals. The SLS-002 product, a drug-device combination consisting of ketamine hydrochloride and a USP aqueous spray solution delivered via a bi-dose nasal device developed by a third party under a license agreement, faces additional regulatory challenges. Manufacturing facilities and contract manufacturers are required to comply with regulations such as current Good Manufacturing Practices (cGMP) and Good Laboratory Practices (GLP) to ensure quality and regulatory compliance. Inadequate manufacturing controls could introduce contaminants or affect product stability, thereby impacting safety and effectiveness. Documentation supporting New Drug Application (NDA) or Marketing Authorization Application (MAA) submissions must be prepared in a timely manner and comply with regulations set by the FDA, EMA, or comparable foreign authorities.
Sources:
Seelos Therapeutics inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Seelos Therapeutics inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
